Physiologically-based pharmacokinetic model for Fentanyl in support of the development of Provisional Advisory Levels.

Provisional Advisory Levels (PALs) are tiered exposure limits for toxic chemicals in air and drinking water that are developed to assist in emergency responses. Physiologically-based pharmacokinetic (PBPK) modeling can support this process by enabling extrapolations across doses, and exposure routes, thereby addressing gaps in the available toxicity data. Here, we describe the development of a PBPK model for Fentanyl - a synthetic opioid used clinically for pain management - to support the establishment of PALs. Starting from an existing model for intravenous Fentanyl, we first optimized distribution and clearance parameters using several additional IV datasets. We then calibrated the model using pharmacokinetic data for various formulations, and determined the absorbed fraction, F, and time taken for the absorbed amount to reach 90% of its final value, t90. For aerosolized pulmonary Fentanyl, F=1 and t90<1 min indicating complete and rapid absorption. The F value ranged from 0.35 to 0.74 for oral and various transmucosal routes. Oral Fentanyl was absorbed the slowest (t90~300 min); the absorption of intranasal Fentanyl was relatively rapid (t90~20-40 min); and the various oral transmucosal routes had intermediate absorption rates (t90~160-300 min). Based on these results, for inhalation exposures, we assumed that all of the Fentanyl inhaled from the air during each breath directly, and instantaneously enters the arterial circulation. We present model predictions of Fentanyl blood concentrations in oral and inhalation scenarios relevant for PAL development, and provide an analytical expression that can be used to extrapolate between oral and inhalation routes for the derivation of PALs.

[1]  L. Mather Clinical Pharmacokinetics of Fentanyl and its Newer Derivatives , 1983, Clinical pharmacokinetics.

[2]  T. Gillespie,et al.  Age and Fentanyl Pharmacokinetics , 1982, Anesthesia and analgesia.

[3]  H. Striebel,et al.  [Pharmacokinetics of intranasal Fentanyl.]. , 1993, Schmerz.

[4]  D. Fung,et al.  Fentanyl Pharmacokinetics in Awake Volunteers , 1980, Journal of clinical pharmacology.

[5]  R. Upton,et al.  Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. , 2008, Clinical therapeutics.

[6]  Q. Schiermeier Hostage deaths put gas weapons in spotlight , 2002, Nature.

[7]  D. Fisher,et al.  PHARMACOKINETICS OF FENTANYL IN THE ELDERLY , 1988 .

[8]  E. Kharasch,et al.  Simultaneous Assessment of Drug Interactions with Low- and High-Extraction Opioids: Application to Parecoxib Effects on the Pharmacokinetics and Pharmacodynamics of Fentanyl and Alfentanil , 2003, Anesthesiology.

[9]  Harvey J Clewell,et al.  Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform , 2006, Journal of toxicology and environmental health. Part A.

[10]  A. Sandler,et al.  A review of the use of fentanyl analgesia in the management of acute pain in adults. , 1999, Anesthesiology.

[11]  V. Sunderland,et al.  Pharmacokinetics of Nasal Fentanyl , 2003 .

[12]  E. Kharasch,et al.  Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[13]  H. Magnussen,et al.  PLASMA FENTANYL CONCENTRATIONS AND THE OCCURRENCE OF RESPIRATORY DEPRESSION IN VOLUNTEERS , 1982 .

[14]  S. Baba,et al.  Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry. , 1984, Anesthesiology.

[15]  Robert A Young,et al.  Overview of the Standing Operating Procedure (SOP) for the development of Provisional Advisory Levels (PALs) , 2009, Inhalation toxicology.

[16]  J. Svensson,et al.  Morphine metabolism in cancer patients on increasing oral doses--no evidence for autoinduction or dose-dependence. , 1983, British journal of clinical pharmacology.

[17]  D. R. Cook,et al.  Double-blind comparison of oral transmucosal fentanyl citrate with oral meperidine, diazepam, and atropine as preanesthetic medication in children with congenital heart disease. , 1991, Anesthesiology.

[18]  E. Hellriegel,et al.  Comparison of Equivalent Doses of Fentanyl Buccal Tablets and Arteriovenous Differences in Fentanyl Pharmacokinetics , 2006, Clinical pharmacokinetics.

[19]  H. W. Striebel,et al.  Pharmakokinetische Studie zur intranasalen Gabe von Fentanyl , 1993, Der Schmerz.

[20]  K. Hildebrand,et al.  A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. , 2006, Pain medicine.

[21]  Sven Björkman,et al.  Comparative physiological pharmacokinetics of fentanyl and alfentanil in rats and humans based on parametric single-tissue models , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[22]  T. Egan,et al.  Dose Proportionality and Pharmacokinetics of Oral Transmucosal Fentanyl Citrate , 1998, Anesthesiology.

[23]  Hudson Rj Variability of fentanyl pharmacokinetics in neonates. , 1986 .

[24]  K. A. East,et al.  Oral Transmucosal Fentanyl Citrate (Lollipop) Premedication in Human Volunteers , 1989, Anesthesia and analgesia.

[25]  Paul S Price,et al.  Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans , 2003, Critical reviews in toxicology.

[26]  Russell D. Wada,et al.  Application of Physiologic Models to Predict the Influence of Changes in Body Composition and Blood Flows on the Pharmacokinetics of Fentanyl and Alfentanil in Patients , 1998, Anesthesiology.

[27]  M. Danhof,et al.  Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory-Depressant Effect of Buprenorphine and Fentanyl in Rats , 2006, Journal of Pharmacology and Experimental Therapeutics.

[28]  Gary M. Pollack,et al.  Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective , 2008, The AAPS Journal.

[29]  Erratum to: A physiologically-based recirculatory meta-model for nasal fentanyl in man , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[30]  M. Jamei,et al.  PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. , 2010, Toxicology.

[31]  S J Farr,et al.  Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. , 1998, British journal of clinical pharmacology.

[32]  T. Hedner,et al.  Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. , 2005, British journal of clinical pharmacology.

[33]  Amin Rostami-Hodjegan,et al.  Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal Pregnancy , 2012, Clinical Pharmacokinetics.

[34]  C. Coté,et al.  Uptake pharmacokinetics of the Fentanyl Oralet® in children scheduled for central venous access removal: implications for the timing of initiating painful procedures , 2002, Paediatric anaesthesia.

[35]  E. Tanaka,et al.  Clinically important pharmacokinetic drug–drug interactions: role of cytochrome P450 enzymes , 1998, Journal of clinical pharmacy and therapeutics.

[36]  Hugh A. Barton,et al.  Database for Physiologically Based Pharmacokinetic (PBPK) Modeling: Physiological Data for Healthy and Health-Impaired Elderly , 2009, Journal of toxicology and environmental health. Part B, Critical reviews.

[37]  H Harashima,et al.  Comparative tissue concentration profiles of fentanyl and alfentanil in humans predicted from tissue/blood partition data obtained in rats. , 1990, Anesthesiology.

[38]  E. Kharasch,et al.  Influence of Hepatic and Intestinal Cytochrome P4503A Activity on the Acute Disposition and Effects of Oral Transmucosal Fentanyl Citrate , 2004, Anesthesiology.

[39]  James C. Scott,et al.  Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. , 1991, Anesthesiology.

[40]  C. Coté,et al.  The Pharmacokinetics of the Intravenous Formulation of Fentanyl Citrate Administered Orally in Children Undergoing General Anesthesia , 2004, Anesthesia and analgesia.

[41]  D. Gardner,et al.  Provisional Advisory Levels (PALs) for acrylonitrile , 2009, Inhalation toxicology.

[42]  B. J. Peterson,et al.  Oral transmucosal fentanyl citrate for analgesia and sedation in the emergency department. , 1991, Annals of emergency medicine.

[43]  D. McClain,et al.  Intravenous fentanyl kinetics , 1980, Clinical pharmacology and therapeutics.

[44]  Nat Rothman,et al.  Physiologically‐Based Pharmacokinetic Modeling of Benzene in Humans: A Bayesian Approach , 2006, Risk analysis : an official publication of the Society for Risk Analysis.

[45]  H. Scheinin,et al.  The Concentration-Effect Relationship of the Respiratory Depressant Effects of Alfentanil and Fentanyl , 2001, Anesthesia and analgesia.

[46]  François Bouzom,et al.  Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? , 2012, Biopharmaceutics & drug disposition.

[47]  S. Harapat,et al.  Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[48]  S. Schug,et al.  Formulations of Fentanyl for the Management of Pain , 2012, Drugs.

[49]  N. Pace,et al.  Oral Transmucosal Fentanyl Citrate Premedication in Children , 1989, Anesthesia and analgesia.

[50]  J. Silverstein,et al.  An Analysis of the Duration of Fentanyl and Its Metabolites in Urine and Saliva , 1993, Anesthesia and analgesia.

[51]  T. Sacco,et al.  Balanced anestesia versus total intravenous anestesia for kidney transplantation. , 2006, Minerva anestesiologica.

[52]  H J Clewell,et al.  Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. , 2000, Environmental health perspectives.

[53]  P M Schlosser,et al.  Haber's rule: a special case in a family of curves relating concentration and duration of exposure to a fixed level of response for a given endpoint. , 2000, Toxicology.

[54]  B. Crotty,et al.  Epidural Fentanyl Effect on Cardiac Output and Hepatic Blood Flow , 1991 .

[55]  Steven Edward Kern,et al.  A pharmacokinetic study to compare two simultaneous 400 μg doses with a single 800 μg dose of oral transmucosal fentanyl citrate , 2003 .

[56]  C. Prys‐roberts,et al.  Ventilatory Depression Related to Plasma Fentanyl Concentrations during and after Anesthesia in Humans , 1983, Anesthesia and analgesia.

[57]  M. Darwish,et al.  Pharmacokinetics and Dose Proportionality of Fentanyl Effervescent Buccal Tablets in Healthy Volunteers , 2005, Clinical pharmacokinetics.

[58]  M. Ashburn,et al.  Absorption and bioavailability of oral transmucosal fentanyl citrate. , 1991, Anesthesiology.

[59]  A. Zwart,et al.  Concentration—time mortality response relationship of irritant and systemically acting vapours and gases , 1986 .

[60]  Harvey J Clewell,et al.  Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling , 2007, Journal of Exposure Science and Environmental Epidemiology.

[61]  S. Björkman Reduction and Lumping of Physiologically Based Pharmacokinetic Models: Prediction of the Disposition of Fentanyl and Pethidine in Humans by Successively Simplified Models , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[62]  D R Stanski,et al.  Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. , 1987, The Journal of pharmacology and experimental therapeutics.

[64]  E. Kharasch,et al.  Influence of Age on the Pharmacokinetics and Pharmacodynamics of Oral Transmucosal Fentanyl Citrate , 2004, Anesthesiology.

[65]  C. Timperley,et al.  Analysis of clothing and urine from Moscow theatre siege casualties reveals carfentanil and remifentanil use. , 2012, Journal of analytical toxicology.

[66]  M. Mcclanahan,et al.  Provisional Advisory Levels (PALs) for phosgene (CG) , 2009, Inhalation toxicology.

[67]  R. Moore,et al.  PLASMA FENTANYL CONCENTRATIONS AND CLINICAL OBSERVATIONS DURING AND AFTER OPERATION , 1979 .

[68]  A. J. MacDonald,et al.  The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride. , 2000, Regulatory toxicology and pharmacology : RTP.

[69]  E. Hellriegel,et al.  Single‐Dose and Steady‐State Pharmacokinetics of Fentanyl Buccal Tablet in Healthy Volunteers , 2007, Journal of clinical pharmacology.

[70]  J Bromilow,et al.  Liver enzyme induction and inhibition: implications for anaesthesia , 2006, Anaesthesia.

[71]  D. Gardner,et al.  Provisional Advisory Levels (PALs) for hydrogen sulfide (H2S) , 2009, Inhalation toxicology.

[72]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[73]  S. Kaasa,et al.  Long term methadone for chronic pain: A pilot study of pharmacokinetic aspects , 2007, European journal of pain.